Brief: U.S. FDA Awards Orphan Drug Designation To Paxalisib For AT/RT, A Rare Form Of Childhood Brain Cancer
17/06/2022 13:14
June 17 (Reuters) - Kazia Therapeutics Ltd KZA.AX :
* US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB
FOR
AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
Source text for Eikon: ID:nPn3P4XpBa
Further company coverage: KZA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsBrief: Kazia Therapeutics Files For Mixed Shelf Of Up To $100 Million – SEC Filing
Brief: Kazia Announces Voluntary Delisting From ASX
Australia's Kazia Therapeutics slumps to 1-yr low on delisting announcement
Brief: Kazia Therapeutics Announces Intention To Voluntarily De-List From ASX
Brief: Kazia Therapeutics Seeks Trading Halt